Table 2.
First author (year) | Design | N of pts | Timing | Prophylaxis | Risk of VTE | Risk of HE /recurrent ICH |
---|---|---|---|---|---|---|
Boeer [40] (1991) |
Prospective | 68 | 2 days vs. 4 days vs. 10 days | UFH 5000 U q8h | Reduction in number of PE in 2 days group (1 vs. 5 vs. 9) | No significant difference |
Wasay [41] (2008) |
Prospective | 458 | 1–6 days | UFH 2500-5000 U bid+GCS vs. GCS alone | No significant difference | No significant difference |
Orken [42] (2009) |
Randomized trial | 75 | 48 h | Enoxaparin 4000 IU qd vs. GCS | No significant difference | No significant difference |
Kiphuth [43] (2009) |
Retrospective | 97 | < 36 h | Enoxaparin 4000 IU qd or dalteparin 2500 IU qd | Not mentioned | 0 at day 2 |
Faust [44] (2017) |
Retrospective | 400 | <48 h vs. ≥48 h | Not mentioned | 0.7% vs. 3.1% (P = 0.17) | 5.6% vs. 5.0% (P = 0.80) |
Ianosi [45] (2019) |
Retrospective | 134 | <48 h vs. ≥48 h | Enoxaparin 2000 IU/4000 IU qd | Not mentioned | No significant difference |
Kananeh [46] (2021) |
Retrospective | 163 | <24 h vs. ≥24 h | UFH 5000 U q8h | Not mentioned | 3.4% vs. 6.7% (P = 0.49) |
Qian [47] (2021) |
Randomized trial | 139 | 24 h vs. 72 h | Enoxaparin 2000 IU bid | No significant difference | No significant difference |
N of pts number of patients; UFH unfractionated heparin; GCS graduated compression stockings; HE hematoma expansion